Healthcare Industry News: BioSyent
News Release - April 10, 2007
BioSyent Announces Start of FeraMAX(TM) Shipments
MISSISSAUGA, ONTARIO--(Healthcare Sales & Marketing Network)--Apr 10, 2007 -- BioSyent Inc. ("BioSyent") (CDNX:RX.V ) is pleased to announce that FeraMAX(TM) shipments to wholesale customers have commenced. FeraMAX(TM) is an oral hematinic that helps the body form red blood cells and is indicated for the prevention and treatment of iron deficiency anemia (IDA). It is formulated with polysaccharide-iron complex (PIC), which provides a non-ionic delivery system that allows the iron ion to be delivered to the bloodstream without coming in to contact with the stomach or upper gastro-intestinal tract. This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects such as nausea, constipation, diarrhea, and epigastric pain associated with many other iron formulations. FeraMAX(TM) is being promoted to Canadian doctors and healthcare professionals by a small specialty sales force.BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Source: BioSyent
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!